L
Lucrezia Verardi
Researcher at Catholic University of the Sacred Heart
Publications - 28
Citations - 256
Lucrezia Verardi is an academic researcher from Catholic University of the Sacred Heart. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 12 publications receiving 92 citations.
Papers
More filters
Journal ArticleDOI
Sarilumab use in severe SARS-CoV-2 pneumonia.
Elisa Gremese,Antonella Cingolani,Silvia Laura Bosello,Stefano Alivernini,Barbara Tolusso,Simone Perniola,Francesco Landi,Maurizio Pompili,Rita Murri,Angelo Santoliquido,Matteo Garcovich,Michela Sali,Gennaro De Pascale,Maurizio Gabrielli,Federico Biscetti,Massimo Montalto,Alberto Tosoni,Giovanni Gambassi,Gian Ludovico Rapaccini,Amerigo Iaconelli,Lorenzo Zileri Del Verme,Luca Petricca,Anna Laura Fedele,Marco Maria Lizzio,Enrica Tamburrini,Gerlando Natalello,L. Gigante,Dario Bruno,Lucrezia Verardi,Eleonora Taddei,Angelo Calabrese,Francesco Lombardi,Roberto Bernabei,Roberto Cauda,Francesco Franceschi,Raffaele Landolfi,Luca Richeldi,Maurizio Sanguinetti,Massimo Fantoni,Massimo Antonelli,Antonio Gasbarrini +40 more
TL;DR: IL-6R inhibition appears to be a potential treatment strategy for severe SARS-CoV-2 pneumonia and intravenous Sarilumab seems a promising treatment approach showing, in the short term, an important clinical outcome and good safety.
Journal ArticleDOI
Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement.
Gerlando Natalello,Giacomo De Luca,L. Gigante,Corrado Campochiaro,Enrico De Lorenzis,Lucrezia Verardi,Annamaria Paglionico,Luca Petricca,Anna Maria Martone,Stefania Calvisi,Marco Ripa,Giulio Cavalli,Emanuel Della-Torre,Moreno Tresoldi,Francesco Landi,Silvia Laura Bosello,Elisa Gremese,Lorenzo Dagna +17 more
TL;DR: Current ill and recovered subjects are characterized by a different distribution of elementary capillaroscopic alterations, resembling acute and post-acute microvascular damage, reminiscent of coronavirus disease-2019.
Journal ArticleDOI
Adult-onset Still's disease following COVID-19 vaccination.
Flavia Leone,Pier Giacomo Cerasuolo,Silvia Laura Bosello,Lucrezia Verardi,Enrica Fiori,Fabrizio Cocciolillo,Biagio Merlino,Angelo Zoli,Maria Antonietta D'Agostino +8 more
Posted ContentDOI
Sarilumab use in severe SARS-CoV-2 pneumonia
Elisa Gremese,Antonella Cingolani,Silvia Laura Bosello,Stefano Alivernini,Barbara Tolusso,Simone Perniola,Francesco Landi,Maurizio Pompili,Rita Murri,Angelo Santoliquido,Matteo Garcovich,Michela Sali,Gennaro De Pascale,Gennaro De Pascale,Maurizio Gabrielli,Federico Biscetti,Massimo Montalto,Alberto Tosoni,Giovanni Gambassi,Gian Ludovico Rapaccini,Amerigo Iaconelli,Lorenzo Zileri Del Verme,Luca Petricca,Anna Laura Fedele,Marco Maria Lizzio,Enrica Tamburrini,Gerlando Natalello,L. Gigante,Dario Bruno,Lucrezia Verardi,Eleonora Taddei,Angelo Calabrese,Francesco Lombardi,Roberto Bernabei,Roberto Cauda,Francesco Franceschi,Raffaele Landolfi,Luca Richeldi,Maurizio Sanguinetti,Massimo Fantoni,Massimo Antonelli,Massimo Antonelli,Antonio Gasbarrini +42 more
TL;DR: IL6−R inhibition appears to be a potential treatment strategy for severe SARS−CoV−2 pneumonia and intravenous Sarilumab seems a promising treatment approach showing, in the short term, an important clinical benefit and good safety.